SCHEMBL1349414

SCHEMBL1349414

N#Cc1cccc(-c2cccc(C3CN(S(=O)(=O)c4ccccc4)CC(=O)N3c3ccccc3)c2)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSG P08311 2/20 0.47
CMA1 P23946 2/20 0.47
PAX8 Q06710 2/20 0.42
KAT6A Q92794 1/20 0.38
ALDH1A1 P00352 2/20 0.37
USP2 O75604 1/20 0.37
HPGD P15428 1/20 0.37
MAPK1 P28482 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
HIF1A Q16665 1/20 0.37
HSD17B10 Q99714 1/20 0.37
KDM2B Q8NHM5 1/20 0.36
PKM P14618 1/20 0.36
DPP4 P27487 1/20 0.36
MCOLN3 Q8TDD5 1/20 0.35
ACLY P53396 1/20 0.35
ESR1 P03372 1/20 0.35
ESR2 Q92731 1/20 0.35
PTGES2 Q9H7Z7 1/20 0.35
RAB9A P51151 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1349030 0.85 NR1H2 (0.41) ALDH1A1USP2HPGDMAPK1SMN1; SMN2
SCHEMBL1347358 0.80 MMP2 (0.44) CTSGCMA1ALDH1A1PKMESR1
SCHEMBL1348981 0.68 NR1H2 (0.42) ALDH1A1PKMRAB9AKMT2A
SCHEMBL1348740 0.67 CMA1 (0.45) CTSGCMA1ALDH1A1PKMRAB9A
SCHEMBL1346988 0.66 NR1H2 (0.44) ALDH1A1USP2HPGDMAPK1SMN1; SMN2
SCHEMBL1348608 0.66 MCL1 (0.43) CTSGCMA1ALDH1A1USP2HPGD
SCHEMBL28787377 0.65 PKM (0.37) CTSGCMA1PAX8ALDH1A1USP2
SCHEMBL15841731 0.65 BCL9 (0.38) CTSGCMA1ALDH1A1PKMRAB9A
SCHEMBL1348906 0.65 ALDH1A1 (0.46) ALDH1A1PKMRAB9AKMT2APOLB
SCHEMBL2961172 0.65 HTT (0.61) CTSGCMA1ALDH1A1USP2HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2288594-B1 IMIDAZOLIDINE DERIVATIVES HOFFMANN LA ROCHE (CH) 2014-07-02 EP disclosed
US-8063088-B2 Imidazolidine derivatives HOFFMANN-LA ROCHE INC. (US) 2011-11-22 US disclosed
EP-2288594-A1 IMIDAZOLIDINE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2011-03-02 EP disclosed
US-20090312382-A1 NOVEL IMIDAZOLIDINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2009-12-17 US disclosed
WO-2009150109-A1 IMIDAZOLIDINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2009-12-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090312382-A1 NOVEL IMIDAZOLIDINE DERIVATIVES NR1H2, NR1H3, NR1D2 CTSG 4280/4885CMA1 4479/4885PAX8 4324/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.